-+ 0.00%
-+ 0.00%
-+ 0.00%

Warner Pharmaceuticals announced that a total of 7 new varieties of the company have entered the national basic drug catalogue. Among them, four products, including colloidal pectin bismuth capsules), acetylcysteine solution for inhalation, ipratropium bromide solution for inhalation, and nifedipine sustained-release tablets, achieved total sales revenue of 132 million yuan in 2025, accounting for 8.78% of the company's revenue in 2025; the first quarter of 2026 achieved total sales revenue of 21.8037 million yuan, accounting for 6.72% of the company's revenue in the first quarter of 2026. There is no sales revenue for other products in 2025 or the first quarter of 2026.

Zhitongcaijing·07/10/2026 08:41:12
Listen to the news
Warner Pharmaceuticals announced that a total of 7 new varieties of the company have entered the national basic drug catalogue. Among them, four products, including colloidal pectin bismuth capsules), acetylcysteine solution for inhalation, ipratropium bromide solution for inhalation, and nifedipine sustained-release tablets, achieved total sales revenue of 132 million yuan in 2025, accounting for 8.78% of the company's revenue in 2025; the first quarter of 2026 achieved total sales revenue of 21.8037 million yuan, accounting for 6.72% of the company's revenue in the first quarter of 2026. There is no sales revenue for other products in 2025 or the first quarter of 2026.